Patients & Families

Grid is committed to advancing our unique strategy to develop better and safer medicines for our patients. This has and will continue to be our sole mission.

Phase 1b study in patients with refractory, advanced stage (III/IV) and recurrent Non-Small Cell Lung Cancer (NSCLC)

Our Phase 1b study, designed to assess the safety, tolerability and Maximum Tolerated Dose of GT103 as a monotherapy in adult subjects with refractory, advanced stage NSCLC was closed to accrual (at our request) in December 2023. We enrolled in total 31 patients with advanced stage lung cancer.

• Additional information on the Phase 1b study can be found on Clinicaltrials.gov.

Phase 2 study in patients with relapsed or refractory metastatic NSCLC

Our Phase 2 GT103 combination trial with Pembrolizumab (Keytruda®) is ongoing but now closed to enrollment.

• Additional information on the Phase 2 study can be found on Clinicaltrials.gov.

For further support or questions contact:
Dr. Edward Patz, MD
CEO
Grid Therapeutics, LLC
edward.patz@gridthr.com